Effectiveness and Safety of Combined Semaglutide and Dapagliflozin Therapy in Type 2 Diabetes: A Retrospective Cohort Study - Cureus

A retrospective cohort study published in Cureus examines the effectiveness and safety of combining semaglutide, a GLP-1 receptor agonist, with dapagliflozin, an SGLT2 inhibitor, for the management of type 2 diabetes. The findings add to a growing body of real-world evidence on GLP-1-based combination regimens.

What the study addresses

GLP-1 receptor agonists and SGLT2 inhibitors each lower blood glucose through distinct mechanisms. Combining the two classes is clinically intuitive—targeting both incretin signaling and renal glucose excretion—but real-world outcomes data remains limited. The Cureus paper reviews retrospective records to assess whether the combination delivers measurable glycemic and metabolic improvements without unacceptable safety tradeoffs.

• Semaglutide acts on GLP-1 receptors to increase insulin secretion and slow gastric emptying.
• Dapagliflozin blocks glucose reabsorption in the proximal renal tubule.
• The study evaluates the paired regimen in a real-world type 2 diabetes population rather than a controlled trial setting.

Why this matters for GLP-1 combination research

Combination therapy is increasingly relevant as clinicians look beyond single-agent GLP-1 dosing to manage complex metabolic disease. Retrospective cohort studies like this one cannot establish causality and are subject to selection bias, but they offer a useful signal: how do these regimens perform outside of randomized controlled trials, in patients who may have comorbidities or inconsistent adherence?

Real-world evidence does not replace randomized trials, but it helps flag whether a mechanistically promising combination holds up in routine clinical practice.

Preliminary and observational

This development should be read as preliminary observational data. Retrospective designs carry inherent limitations: no randomization, potential confounding by indication, and reliance on existing medical records. The study contributes to the evidence base but does not constitute definitive guidance on prescribing semaglutide alongside dapagliflozin.

Key caveats

1. Retrospective data cannot prove the combination caused observed outcomes.
2. Sample characteristics and follow-up duration may limit generalizability.
3. Safety signals require confirmation in larger, prospective cohorts.